Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases

Cancer Treatment Reviews

Volumn 40, Issue 6, 2014, Pages 716-722

  Zimmermann, Stefan ^a   Dziadziuszko, Rafal ^b   Peters, Solange ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Brain metastasis; Driver oncogenes; Non small cell lung cancer (NSCLC); Stereotactic radiotherapy; Targeted treatment

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CRIZOTINIB; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; METHOTREXATE; NAVELBINE; PACLITAXEL; PEMETREXED; TEMOZOLOMIDE; TOPOTECAN;

BLOOD BRAIN BARRIER; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RESEARCH; HUMAN; LUNG NON SMALL CELL CANCER; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SYSTEMIC THERAPY; TREATMENT INDICATION;

BRAIN METASTASIS; DRIVER ONCOGENES; NON SMALL CELL LUNG CANCER (NSCLC); STEREOTACTIC RADIOTHERAPY; TARGETED TREATMENT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; INCIDENCE; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PROGNOSIS; QUINAZOLINES; RADIOSURGERY; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84899972290     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2014.03.005     Document Type: Review

References (99)

1. Rizzi A., et al. Lung cancer with a single brain metastasis: therapeutic options. Tumori 1990, 76(6):579-581.
2. Yawn B.P., et al. Temporal and gender-related trends in brain metastases from lung and breast cancer. Minn Med 2003, 86(12):32-37.
3. Delattre J.Y., et al. Distribution of brain metastases. Arch Neurol 1988, 45(7):741-744.
4. Davis F.G., et al. Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data. Neuro Oncol 2012, 14(9):1171-1177.
5. Smedby K.E., et al. Brain metastases admissions in Sweden between 1987 and 2006. Br J Cancer 2009, 101(11):1919-1924.
6. Sperduto P.W., et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012, 30(4):419-425.
7. Blankenburg T., et al. Prognostic relevance of the metastatic localisation in patients with stage IV NSCLC - results of a prospective epidemiological study. Pneumologie 2010, 64(11):679-685.
8. Peters S., et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012, 23(Suppl. 7):vii56-vii64.
9. Patchell R.A., et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990, 322(8):494-500.
10. Vecht C.J., et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery?. Ann Neurol 1993, 33(6):583-590.
11. Andrews D.W., et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004, 363(9422):1665-1672.
12. Ostermann S., et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 2004, 10(11):3728-3736.
13. Shapiro W.R., Young D.F., Mehta B.M. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 1975, 293(4):161-166.
14. Sung C., et al. A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid. Cancer Res 1994, 54(19):5118-5122.
15. Abbott N.J., et al. Structure and function of the blood-brain barrier. Neurobiol Dis 2010, 37(1):13-25.
16. Ohtsuki S., Terasaki T. Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm Res 2007, 24(9):1745-1758.
17. Holash J., et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999, 284(5422):1994-1998.
18. Fidler I.J., et al. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol 2002, 3(1):53-57.
19. Cortes J., et al. Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer. Oncology 2003, 64(1):28-35.
20. Minotti V., et al. Chemotherapy with cisplatin and teniposide for cerebral metastases in non-small cell lung cancer. Lung Cancer 1998, 20(2):93-98.
21. Fujita A., et al. Combination chemotherapy of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with brain metastases from non-small cell lung cancer. Oncology 2000, 59(4):291-295.
22. Franciosi V., et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 1999, 85(7):1599-1605.
23. Cotto C., et al. A phase II trial of fotemustine and cisplatin in central nervous system metastases from non-small cell lung cancer. Eur J Cancer 1996, 32A(1):69-71.
24. Bernardo G., et al. First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: a phase II study. Cancer Invest 2002, 20(3):293-302.
25. Robinet G., et al. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Francais de Pneumo-Cancerologie (GFPC) Protocol 95-1. Ann Oncol 2001, 12(1):59-67.
26. Barlesi F., et al. Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01). Ann Oncol 2011, 22(11):2466-2470.
27. Bailon O., et al. Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma. Neuro Oncol 2012, 14(4):491-495.
28. Bearz A., et al. Activity of pemetrexed on brain metastases from non-small cell lung cancer. Lung Cancer 2010, 68(2):264-268.
29. Abrey L.E., et al. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 2001, 53(3):259-265.
30. Christodoulou C., et al. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 2001, 12(2):249-254.
31. Dziadziuszko R., et al. Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC lung cancer group (08965). Eur J Cancer 2003, 39(9):1271-1276.
32. Verger E., et al. Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys 2005, 61(1):185-191.
33. Antonadou D., et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 2002, 20(17):3644-3650.
34. Chua D., et al. Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-label phase II study. Clin Lung Cancer 2010, 11(3):176-181.
35. Guerrieri M., et al. A randomised phase III study of palliative radiation with concomitant carboplatin for brain metastases from non-small cell carcinoma of the lung. Lung Cancer 2004, 46(1):107-111.
36. Neuhaus T., et al. A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer. Br J Cancer 2009, 100(2):291-297.
37. Soussain C., et al. CNS complications of radiotherapy and chemotherapy. Lancet 2009, 374(9701):1639-1651.
38. Tsao M.N., et al. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev 2012, 4:CD00869.
39. Lee D.H., et al. Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole-brain radiotherapy administered first: result of a randomized pilot study. Cancer 2008, 113(1):143-149.
40. Tallet A.V., et al. Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment. Radiat Oncol 2012, 7:77.
41. Ahles T.A., et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol 2010, 28(29):4434-4440.
42. de Ruiter M.B., et al. Cerebral hyporesponsiveness and cognitive impairment 10years after chemotherapy for breast cancer. Hum Brain Mapp 2011, 32(8):1206-1219.
43. Koppelmans V., et al. Neuropsychological performance in survivors of breast cancer more than 20years after adjuvant chemotherapy. J Clin Oncol 2012, 30(10):1080-1086.
44. Castellon S.A., et al. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 2004, 26(7):955-969.
45. Aoyama H., et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006, 295(21):2483-2491.
46. Kocher M., et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 2011, 29(2):134-141.
47. Chang E.L., et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 2009, 10(11):1037-1044.
48. Sperduto P., Shanley R., Luo X. Secondary analysis of RTOG 9508, a phase 3 randomized trial of whole brain radiation therapy (WBRT) versus WBRT plus stereotactic radiosurgery (SRS) in patients with 1-3 brain metastases poststratified by the graded prognostic assessment (GPA). Int J Radiat Oncol Biol Phys 2013, 87. [2S:S51 (abstr. 123)].
49. Lagerwaard F.J., et al. Whole-brain radiotherapy with simultaneous integrated boost to multiple brain metastases using volumetric modulated arc therapy. Int J Radiat Oncol Biol Phys 2009, 75(1):253-259.
50. Rodrigues G., et al. Phase I trial of simultaneous in-field boost with helical tomotherapy for patients with one to three brain metastases. Int J Radiat Oncol Biol Phys 2011, 80(4):1128-1133.
51. Gondi V., Tome W.A., Mehta M.P. Why avoid the hippocampus? A comprehensive review. Radiother Oncol 2010, 97(3):370-376.
52. Gondi V., et al. Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: safety profile for RTOG 0933. Radiother Oncol 2010, 95(3):327-331.
53. Wan J.F., et al. Implications for preserving neural stem cells in whole brain radiotherapy and prophylactic cranial irradiation: a review of 2270 metastases in 488 patients. J Radiat Res 2013, 54(2):285-291.
54. Prokic V., et al. Whole brain irradiation with hippocampal sparing and dose escalation on multiple brain metastases: a planning study on treatment concepts. Int J Radiat Oncol Biol Phys 2013, 85(1):264-270.
55. Brown P.D., et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol 2013, 15(10):1429-1437.
56. Shaw M.G., Ball D.L. Treatment of brain metastases in lung cancer: strategies to avoid/reduce late complications of whole brain radiation therapy. Curr Treat Options Oncol 2013, 14(4):553-567.
57. Mok T.S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361(10):947-957.
58. Rosell R., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13(3):239-246.
59. Sequist L.V., et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 2011, 22(12):2616-2624.
60. Villalva C., et al. EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients. Cancer Med 2013, 2(3):296-304.
61. Sun M., et al. HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin Cancer Res 2009, 15(15):4829-4837.
62. Cortot A.B., et al. KRAS mutation status in primary nonsmall cell lung cancer and matched metastases. Cancer 2010, 116(11):2682-2687.
63. Cappuzzo F., et al. Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). Lung Cancer 2003, 41(2):227-231.
64. Namba Y., et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. Clin Lung Cancer 2004, 6(2):123-128.
65. Porta R., et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J 2011, 37(3):624-631.
66. Park S.J., et al. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer 2012, 77(3):556-560.
67. Kim J.E., et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer 2009, 65(3):351-354.
68. Li Z. The retrospective analysis of the frequency of EGFR mutations and the efficacy of gefitinib in NSCLC patients with brain metastasis. J Clin Oncol 2011, 29(Suppl.). [abstr. e18065].
69. Eichler A.F., et al. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol 2010, 12(11):1193-1199.
70. Katayama T., et al. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol 2009, 4(11):1415-1419.
71. Togashi Y., et al. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol 2012, 70(3):399-405.
72. Wang M. Cerebral penetration of gefitinib in patients with lung adenocarcinoma. J Clin Oncol 2011, 29(Suppl.). [abstr. 7608].
73. Lee E., et al. Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer. J Thorac Oncol 2013, 8(8):1069-1074.
74. Clarke J.L., et al. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 2010, 99(2):283-286.
75. Grommes C., et al. "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol 2011, 13(12):1364-1369.
76. Togashi Y., et al. Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. Cancer Chemother Pharmacol 2011, 68(4):1089-1092.
77. Ruppert A.M., et al. EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up. Eur Respir J 2009, 33(2):436-440.
78. Welsh J.W., et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol 2013, 31(7):895-902.
79. Sperduto P.W., et al. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: radiation therapy oncology group 0320. Int J Radiat Oncol Biol Phys 2013, 85(5):1312-1318.
80. Iuchi T., et al. Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer 2013, 82(2):282-287.
81. Kaneda H., Okamoto I., Nakagawa K. Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer. J Thorac Oncol 2013, 8(4):e32-e33.
82. Maillet D., et al. Ineffectiveness of crizotinib on brain metastases in two cases of lung adenocarcinoma with EML4-ALK rearrangement. J Thorac Oncol 2013, 8(4):e30-e31.
83. Crino, L. Clinical experience with crizotinib in patients (pts) with advanced ALK+ non-small cell lung cancer (NSCLC) and brain metastases ECCO Meeting, 2013.
84. Shaw A.T., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013, 368(25):2385-2394.
85. Camidge R. Progression-free survival (PFS) from a phase I study of crizotinib (PF02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol 2011, 29(Suppl.):a2501.
86. Camidge R. Progression-free survival (PFS) from a phase I study of crizotinib (PF02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol 2011, 29(Suppl.):a2501.
87. Otterson G.A. Clinical characteristics of ALK+ NSCLC patients (pts) treated with crizotinib beyond disease progression (PD): potential implications for management. J Clin Oncol 2012, 30(Suppl.). [abstr. 7600].
88. Costa D.B., et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 2011, 29(15):e443-e445.
89. Kim Y.H., et al. High-dose crizotinib for brain metastases refractory to standard-dose crizotinib. J Thorac Oncol 2013, 8(9):e85-e86.
90. Takeda M., Okamoto I., Nakagawa K. Clinical impact of continued crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement. J Thorac Oncol 2013, 8(5):654-657.
91. Camidge R. First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: updated results. J Clin Oncol 2013, 31(Suppl.). [abstr. 8031].
92. Shaw A.T. Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC. J Clin Oncol 2013, 31(Suppl.). [abstr. 8010].
93. Nakagawa K. A phase I/II study with a highly selective ALK inhibitor CH5424802 in ALK-positive non-small cell lung cancer (NSCLC) patients: updated safety and efficacy results from AF-001JP. J Clin Oncol 2013, 31(Suppl.). [abstr. 8033].
94. Dziadziuszko K., Szurowska E., Pienkowska J., Jassem J., Dziadziuszko R. Miliary Brain Metastases in a Patient with ROS1-Rearranged Lung Adenocarcinoma: A Case Report. J Thorac Oncol 2014, 9(5):e34-e36.
95. Sandler A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355(24):2542-2550.
96. Reck M., et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010, 21(9):1804-1809.
97. Soria J.C., et al. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol 2013, 24(1):20-30.
98. Socinski M.A., et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 2009, 27(31):5255-5261.
99. Besse B. Final overall survival (OS) results of a noncomparative phase II study of bevacizumab (B) plus first-line chemotherapy or second-line erlotinib (E) in nonsquamous NSCLC (ns-NSCLC) patients with asymptomatic untreated brain metastases (BM) (BRAIN). J Clin Oncol 2013, 31(Suppl.). [abstr. 8059].